FDA Approves Pfizer’s HYMPAVZI for Hemophilia A and B Treatment without Inhibitors

Phil Gattone said, “We greatly appreciate Pfizer’s innovative efforts in developing this novel treatment option that addresses some of the ongoing challenges faced by people with hemophilia A and B. The availability of this therapy represents a powerful step forward in advancing care for more individuals and families in the bleeding disorders community.” Learn more.

Source: National Bleeding Disorders Foundation, October 2024